Resultados da pesquisa - transl lung ((cancer res) or (cancer recent))

Pesquisas alternativas:
cancer recent » cancer report (Expandir a Pesquisa), cancer receiving (Expandir a Pesquisa)
transl lung » transoral lung (Expandir a Pesquisa), transl dunja (Expandir a Pesquisa), cranial lung (Expandir a Pesquisa)
cancer res » cancer re (Expandir a Pesquisa), cancer real (Expandir a Pesquisa), cancer read (Expandir a Pesquisa)

61

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

Por Kohno, Takashi, Nakaoku, Takashi, Tsuta, Koji, Tsuchihara, Katsuya, Matsumoto, Shingo, Yoh, Kiyotaka, Goto, Koichi
Publicado no Transl Lung Cancer Res (2015)

“... recently identified as new targetable genetic aberrations in cases of non-small cell lung cancer (NSCLC...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

62

Exogenous glutathione contributes to cisplatin resistance in lung cancer A549 cells

Exogenous glutathione contributes to cisplatin resistance in lung cancer A549 cells

Por Lan, Dong, Wang, Li, He, Rongquan, Ma, Jie, Bin, Yehong, Chi, Xiaojv, Chen, Gang, Cai, Zhengwen
Publicado no Am J Transl Res (2018)

“... is associated with resistance of non-small cell lung cancer (NSCLC) cell lines to cisplatin (CDDP). It is well...”
Obter o texto integral
Obter o texto integral

Artigo

63

Revisiting the role of COX-2 inhibitor for non-small cell lung cancer

Revisiting the role of COX-2 inhibitor for non-small cell lung cancer

Por Yokouchi, Hiroshi, Kanazawa, Kenya
Publicado no Transl Lung Cancer Res (2015)

“... has some efficacy for non-small cell lung cancer (NSCLC). However, two phase III clinical trials using...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

64

The clinical utility of tumor mutational burden in non-small cell lung cancer

The clinical utility of tumor mutational burden in non-small cell lung cancer

Por Greillier, Laurent, Tomasini, Pascale, Barlesi, Fabrice
Publicado no Transl Lung Cancer Res (2018)

“...Despite advances made during the last two decades, lung cancer remains the leading cause of cancer...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

65

Targeting MET and EGFR in NSCLC—what can we learn from the recently reported phase III trial of onartuzumab in combination with erlotinib in advanced non-small cell lung cancer?

Targeting MET and EGFR in NSCLC—what can we learn from the recently reported phase III trial of onartuzumab in combination with erlotinib in advanced non-small cell lung cancer?

Por Charakidis, Michail, Boyer, Michael
Publicado no Transl Lung Cancer Res (2014)

Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

66

Is chest radiation now a classical practice for extensive small cell lung cancer?

Is chest radiation now a classical practice for extensive small cell lung cancer?

Por Van Houtte, Paul, Moretti, Luigi, Roelandts, Martine
Publicado no Transl Lung Cancer Res (2015)

“...The recent phase III published by Slotman et al. addressed the question of additional chest...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

67

Is surgery still the optimal treatment for stage I non-small cell lung cancer?

Is surgery still the optimal treatment for stage I non-small cell lung cancer?

Por Moghanaki, Drew, Chang, Joe Y.
Publicado no Transl Lung Cancer Res (2016)

Assuntos: “...Review Article on Non-Small Cell Lung Cancer...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

68

Targeted therapy for non-small cell lung cancer: current standards and the promise of the future

Targeted therapy for non-small cell lung cancer: current standards and the promise of the future

Por Chan, Bryan A., Hughes, Brett G.M.
Publicado no Transl Lung Cancer Res (2015)

“...In recent years, there has been a major paradigm shift in the management of non-small cell lung...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

69

Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer

Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer

Por Mohan, Sumitra, Chemi, Francesca, Brady, Ged
Publicado no Transl Lung Cancer Res (2017)

“... of cancers, including lung cancer, the precise clinical utility of CTCs remains to be established. The rarity...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

70

Proton therapy for post-operative radiation therapy of non-small cell lung cancer

Proton therapy for post-operative radiation therapy of non-small cell lung cancer

Por Shepherd, Annemarie Fernandes
Publicado no Transl Lung Cancer Res (2018)

“... non-small cell lung cancer (NSCLC) with N2 mediastinal nodal involvement after surgical resection...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

71

Lung cancer diagnosis and staging in the minimally invasive age with increasing demands for tissue analysis

Lung cancer diagnosis and staging in the minimally invasive age with increasing demands for tissue analysis

Por Folch, Erik, Costa, Daniel B., Wright, Jeffrey, VanderLaan, Paul A.
Publicado no Transl Lung Cancer Res (2015)

“...The diagnosis and staging of patients with lung cancer in recent decades has increasingly relied...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

72

Immunotherapy in locally-advanced non-small cell lung cancer: releasing the brakes on consolidation?

Immunotherapy in locally-advanced non-small cell lung cancer: releasing the brakes on consolidation?

Por Berman, Abigail T., Simone, Charles B.
Publicado no Transl Lung Cancer Res (2016)

“...Locally-advanced non-small cell lung cancer (LA-NSCLC) is optimally treated with definitive...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

73

Predictive models for customizing chemotherapy in advanced non-small cell lung cancer (NSCLC)

Predictive models for customizing chemotherapy in advanced non-small cell lung cancer (NSCLC)

Por Bonanno, Laura
Publicado no Transl Lung Cancer Res (2013)

“...-small cell lung cancer (NSCLC) patients is the use of a platinum-based chemotherapy combination...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

74

Tumor mutational burden in non-small cell lung cancer—the pathologist’s point of view

Tumor mutational burden in non-small cell lung cancer—the pathologist’s point of view

Por Penault-Llorca, Frédérique, Radosevic-Robin, Nina
Publicado no Transl Lung Cancer Res (2018)

“...In non-small cell lung cancer (NSCLC), the pathologist has contributed to the development...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

75

P41. Scedosporium apiospermum mycetoma in a lung cancer patient—case report

P41. Scedosporium apiospermum mycetoma in a lung cancer patient—case report

Por Alevizopoulos, Nektarios, Laskarakis, Apostolos, Vagdatlis, Theodoros, Ntalapera, Vasiliki, Skoula, Anna, Tegos, Theodoros, Argirakos, Theodoros, Margariti, Charis, Vaslamatzis, Michail
Publicado no Transl Lung Cancer Res (2014)

“... in a lung cancer patient host. METHODS AND RESULTS: A 72-year-old man was consecutively admitted in our...”
Obter o texto integral
Obter o texto integral

Artigo

76

ALK and ROS1 as a joint target for the treatment of lung cancer: a review

ALK and ROS1 as a joint target for the treatment of lung cancer: a review

Por Puig de la Bellacasa, Raimon, Karachaliou, Niki, Estrada-Tejedor, Roger, Teixidó, Jordi, Costa, Carlota, Borrell, José I.
Publicado no Transl Lung Cancer Res (2013)

“..., including non-small cell lung cancer (NSCLC). ALK fusions have gain of function properties while activating...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

77

MET genetic lesions in non-small-cell lung cancer: pharmacological and clinical implications

MET genetic lesions in non-small-cell lung cancer: pharmacological and clinical implications

Por Zorzetto, Michele, Ferrari, Simona, Saracino, Laura, Inghilleri, Simona, Stella, Giulia M
Publicado no Transl Lung Cancer Res (2012)

“...Lung cancer is the leading cause of death for solid tumors worldwide with an annual mortality...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

78

Erlotinib in patients with advanced non-small-cell lung cancer: A meta-analysis

Erlotinib in patients with advanced non-small-cell lung cancer: A meta-analysis

Por Gao, Hui, Ding, Xin, Wei, Dong, Cheng, Peng, Su, Xiaomei, Liu, Huanyi, Aziz, Fahad, Wang, Daoyuan, Zhang, Tao
Publicado no Transl Lung Cancer Res (2012)

“... inhibitor with single-agent activity in patients with non–small-cell lung cancer (NSCLC). In this article...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

79

Histopathologic and molecular approach to staging of multiple lung nodules

Histopathologic and molecular approach to staging of multiple lung nodules

Por Schneider, Frank, Dacic, Sanja
Publicado no Transl Lung Cancer Res (2017)

Assuntos: “...Review Article on Update on Pathology and Predictive Biomarkers of Lung Cancer...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

80

Circulating tumor cells versus circulating tumor DNA in lung cancer—which one will win?

Circulating tumor cells versus circulating tumor DNA in lung cancer—which one will win?

Por Calabuig-Fariñas, Silvia, Jantus-Lewintre, Eloísa, Herreros-Pomares, Alejandro, Camps, Carlos
Publicado no Transl Lung Cancer Res (2016)

“... precise molecular data useful for improving the clinical management of lung cancer patients as well as a...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

[1]
Anterior
1
2
3
4
5
6
7
8
9
Seguinte
[9]